Popular ingredients do not mean that they can be declared casually

1. First give a conclusion: what does this question really determine?

The active ingredient chain of evidence must answer at least five things: who is the raw material, what are the specifications, how much is actually added to the finished product, whether it is still identifiable after processing and storage, and what type of evidence supports the claim. The promotional page of the raw material supplier can only be used as a clue and cannot automatically prove that your finished product achieves the same effect.

This article does not reduce the evidence chain for popular skin care active ingredients to a single number or empirical slogan. The project should clearly describe the product definition, target market, sample version, acceptance criteria and responsible person, and then use records to verify each step.

• Ingredient identity: INCI, trade name, manufacturer, batch and specification cannot be mixed.
• Effective substance content: The purchasing concentration and formula input amount need to be converted into the actual level in the finished product
• Dosage form environment: pH, temperature, oxidation, light, and ions can affect stability
• Claim strength: different levels of evidence for ingredient communication, mechanism description, and human efficacy claims
• Target group: general adults, sensitive skin or special use areas requiring different risk assessments

2. Establish a decision matrix: answer these variables first

The project meeting should confirm item by item: 1. Identity of raw materials: INCI, trade name, manufacturer, batch and specification cannot be mixed; 2. Content of active substance: purchase concentration and formula dosage need to be converted into actual levels in the finished product; 3. Dosage form environment: pH, temperature, oxidation, light and ions will affect stability; 4. Claim strength: different levels of evidence for ingredient communication, mechanism description and human efficacy claims; 5. Target group: ordinary adults, sensitive skin or special use parts require different risk assessments. Changes in any of these variables may trigger recalculation of formulas, packaging materials, quotations, tests, labels or delivery dates.

It is recommended that brands divide each variable into four states: "frozen, pending verification, replaceable, and irreplaceable". Unfrozen matters are entered into the risk list, and the decision date and approver are marked to avoid repetition of oral opinions after proofing.

3. Executable process: from requirements to frozen version

The recommended process is: 1. Establish a raw material master file and check the COA, specifications, safety data and regulatory status; 2. Complete the formula calculation, record the actual input and active material conversion caliber; 3. Evaluate dissolution, compatibility, pH, heat treatment and storage stability; 4. Select literature, raw material data, laboratory testing or human evaluation based on the claim; 5. Map the claim text and evidence conclusions one by one and conduct compliance review; 6. Keep the traceability chain of batch raw materials, production records and finished product testing after mass production. Each step should have inputs, outputs, completion conditions, and a person responsible for the next step.

The key to the process is not that more forms are better, but that samples, formulas, packaging materials, tests and labels use the same version number. Any sample that cannot be traced back to specific raw materials, processes and packaging should not be directly used as a basis for mass production.

• Establish raw material master file and check COA, specifications, safety information and regulatory status
• Complete the formula calculation and record the actual feed and active material conversion caliber
• Evaluate solubility, compatibility, pH, heat treatment and storage stability
• Select literature, ingredient data, laboratory tests, or human evaluations based on claims
• Map claim text and evidence conclusions item by item and conduct compliance review
• After mass production, keep the traceability chain of batch raw materials, production records and finished product testing

4. Evidence Map: Which documents can support the judgment?

It is recommended to establish an evidence index, which at least includes: 1. Supplier name, raw material batch COA and specifications; 2. Formula version, feeding record and active ingredient conversion table; 3. Stability or necessary content change data; 4. Efficacy claim evaluation summary and applicable boundaries; 5. Consistency review of labels, details pages, live broadcast scripts and test conclusions. The evidence needs to indicate the source, date, version, applicable products, applicable markets and custodian.

Supplier statements, laboratory reports, regulatory texts, and internal records have varying probative powers. When citing data, the conclusion should be limited to its sample, method and scope of application. Raw material data should not be directly extrapolated to all finished product conclusions.

• Supplier name, raw material batch COA and specifications
• Formula version, feeding record and active ingredient conversion table
• Stability or necessary content change data
• Efficacy claim evaluation summary and applicable boundaries
• Consistency review of labels, detail pages, live broadcast scripts and test conclusions

5. Cost,MOQ How should it be separated from the cycle?

Quotation and scheduling will at least consider: 1. Procurement of high-purity or patented raw materials MOQ The delivery time may be higher than that of common raw materials; 2. Quantitative testing usually requires appropriate methods, standards and laboratory capabilities; 3. The effective ratio of compound raw materials will change the true cost; 4. The stacking of multiple popular ingredients will increase the complexity of formula, stability and claim management; 5. The samples, cycles and indicators of human efficacy evaluation will significantly affect the budget. The same "unit price" may include different service boundaries and must therefore be compared using the same quantity, quality standards, data requirements and delivery location.

It is recommended to divide the total cost into one-time development fee, unit variable cost, testing compliance fee, residual material loss preparation, logistics warehousing and risk reserve; divide the cycle into demand freezing, proofing, testing, packaging materials, production scheduling, inspection and delivery, and indicate the starting conditions respectively.

• Procurement of high-purity or proprietary raw materials MOQ and delivery time may be higher than that of general raw materials
• Quantitative testing often requires appropriate methods, standards and laboratory capabilities
• The effective ratio of compound raw materials will change the true cost
• Stacking multiple popular ingredients will increase the complexity of formula, stability and claim management
• The sample, period and indicators of human efficacy evaluation can significantly affect the budget

6. Quality control: converting from sample indicators to mass production standards

Quality control cannot just say "consistent with the sample". Measurable indicators should be written into specifications, and color, aroma, skin feel and appearance should be managed through standard samples, limit samples, controlled light sources or agreed methods, and first article, inspection, finished product inspection and retention samples should be set up.

Records directly related to this topic include: 1. Raw material access and supplier evaluation form; 2. COA, specifications,SDS and regulatory statements; 3. Formula calculation, weighing and production records; 4. Stability, efficacy and safety evaluation data; 5. Claim evidence index and version approval records. Sampling, re-inspection, deviation and release authority must also be clear to ensure that mass production batches can answer "who released when and based on what evidence".

• Raw material access and supplier evaluation form
• COA, specifications,SDS and regulatory statements
• Formula calculation, weighing and production records
• Stability, efficacy and safety evaluation information
• Claim evidence index and version approval record

7. Compliance and target market: Don’t regard a report as a global passport

The judgment of the target market should cover: 1. Chinese efficacy claims should select evaluation basis according to specifications and disclose the summary; 2. EU safety assessment and PIF require consistent raw material and formula information; 3. US labeling and advertising claims cannot allow products to enter drug supervision for therapeutic purposes. Regulations, system certification, raw material documentation, product testing and market registration solve different problems respectively and cannot be lumped together.

Brands, responsible entities, factories, raw material suppliers and third-party laboratories have different roles. Factories can provide manufacturing and quality documents, but specific product labeling, claims, and marketing responsibilities still need to be independently verified by sales market.

• China's efficacy claims should select evaluation basis according to standards and make the summary public
• EU safety assessment and PIF require consistent raw material and formula information
• U.S. labeling and advertising claims do not allow products to fall under drug regulation due to therapeutic intent

8. The most common failure modes and key points to avoid pitfalls

The most common problems in project review include: 1. Treating the total input amount of compound raw materials as the content of a single active substance; 2. Citing in vitro or raw material research, but writing it as the human body effect of the finished product; 3. Only looking at the ingredient list and sorting, without looking at the raw material concentration and formula process; 4. Using old specifications, testing and publicity data after changing suppliers; 5. Using expressions such as "treating, repairing diseases, medical grade" that exceed the boundaries of cosmetics. These problems are often not that the technology is completely impossible, but that the key conditions are not frozen in advance.

For each high-risk item, six columns are established: probability of occurrence, impact, prevention, monitoring, correction, and responsible person. When deviations occur, isolate the affected batches and versions first, and then investigate the cause to avoid using the next round of samples to cover up the previous round of problems.

• Treat the total amount of compound raw materials as the content of a single active substance
• Citing in vitro or raw material research, but writing about the human body effects of the finished product
• Only look at the ingredient list for sorting, not the raw material concentration and formula process
• Keep old specs, testing and promotional data after changing suppliers
• Use expressions such as "treating, repairing diseases, medical grade" that go beyond the boundaries of cosmetics

9. What attachments should be included in procurement and contracts?

The contract attachments must at least quote: 1. Raw material access and supplier evaluation form; 2. COA, specifications,SDS and regulatory statements; 3. Formula calculation, weighing and production records; 4. Stability, efficacy and safety evaluation data; 5. Claim evidence index and version approval records. When third-party packaging materials, raw materials or testing are involved, brand approval, supplier responsibilities, data delivery, change notifications and post-expiration handling must also be clearly stated.

The delivery terms should define the starting point, brand feedback suspension, supplier extension, retesting, force majeure and release mechanism; the acceptance terms should define the method, sample, objection period, re-inspection and non-conformity disposal.

10. Implementation suggestions for brands

A more prudent implementation method is: 1. Determine consumer problems and verifiable results first, and then select ingredients; 2. Separate "what is added" and "what can be proved" into two tables; 3. Prioritize establishing complete evidence for a few core ingredients instead of stacking long ingredient lists. Turning each suggestion into a person responsible and a date takes the step from reading the guide to project management.

YOU MIRACLE It is recommended that brands complete a one-page project brief before entering samples and quotations. The clearer the information, the more accurately factories can evaluate formulas, packaging materials, testing,MOQ and delivery time; when the information is unclear, the lowest quotation is usually the most difficult to use as the final cost.

• Identify consumer problems and verifiable results before selecting ingredients
• Divide "what is added" and "what can be proved" into two tables
• Prioritize building complete evidence for a few core ingredients rather than stacking long ingredient lists